Litcius/Paper detail

A randomised phase II study of oxaliplatin/5-FU (mFOLFOX) versus irinotecan/5-FU (mFOLFIRI) chemotherapy in locally advanced or metastatic biliary tract cancer refractory to first-line gemcitabine/cisplatin chemotherapy

In Sil Choi, Ki Hwan Kim, Ju Hyun Lee, Koung Jin Suh, Ji‐Won Kim, Jin Hyun Park, Yu Jung Kim, Jin-Soo Kim, Jee Hyun Kim, Jin Won Kim

2021European Journal of Cancer59 citationsDOI

Topics & Concepts

OxaliplatinGemcitabineMedicineAmpulla of VaterInternal medicineGastroenterologyChemotherapyCisplatinIrinotecanOncologyColorectal cancerCarcinomaCancerCholangiocarcinoma and Gallbladder Cancer StudiesGallbladder and Bile Duct DisordersHepatocellular Carcinoma Treatment and Prognosis
A randomised phase II study of oxaliplatin/5-FU (mFOLFOX) versus irinotecan/5-FU (mFOLFIRI) chemotherapy in locally advanced or metastatic biliary tract cancer refractory to first-line gemcitabine/cisplatin chemotherapy | Litcius